Global Urologyand Pelvic Health Reporting Unit — Net Sales
Boston Scientific Global Urologyand Pelvic Health Reporting Unit — Net Sales increased by 5.3% to $718.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.0%, from $630.00M to $718.00M. Over 4 years (FY 2021 to FY 2025), Global Urologyand Pelvic Health Reporting Unit — Net Sales shows an upward trend with a 14.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong product adoption, successful market penetration, or expansion of the urology portfolio, while a decrease may signal competitive pressure or reduced demand for these specific medical procedures.
Detailed definition
This metric represents the total revenue generated from the sale of medical devices and products within the Urology and...
Peer comparison
Comparable to specialized medical device segment revenues at peer firms, often evaluated against broader medtech growth benchmarks and specific urology market growth rates.
bsx_segment_urology_net_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $397.00M | $384.00M | $441.00M | $413.00M | $450.00M | $433.00M | $477.00M | $469.00M | $485.00M | $483.00M | $527.00M | $513.00M | $525.00M | $532.00M | $630.00M | $633.00M | $676.00M | $682.00M | $718.00M |
| QoQ Change | — | -3.3% | +14.8% | -6.3% | +9.0% | -3.8% | +10.2% | -1.7% | +3.4% | -0.4% | +9.1% | -2.7% | +2.3% | +1.3% | +18.4% | +0.5% | +6.8% | +0.9% | +5.3% |
| YoY Change | — | — | — | — | +13.4% | +12.8% | +8.2% | +13.6% | +7.8% | +11.5% | +10.5% | +9.4% | +8.2% | +10.1% | +19.5% | +23.4% | +28.8% | +28.2% | +14.0% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Boston Scientific's global urologyand pelvic health reporting unit — net sales?
- Boston Scientific (BSX) reported global urologyand pelvic health reporting unit — net sales of $718.00M in Q4 2025.
- How has Boston Scientific's global urologyand pelvic health reporting unit — net sales changed year-over-year?
- Boston Scientific's global urologyand pelvic health reporting unit — net sales increased by 14.0% year-over-year, from $630.00M to $718.00M.
- What is the long-term trend for Boston Scientific's global urologyand pelvic health reporting unit — net sales?
- Over 4 years (2021 to 2025), Boston Scientific's global urologyand pelvic health reporting unit — net sales has grown at a 14.4% compound annual growth rate (CAGR), from $1.58B to $2.71B.
- What does global urologyand pelvic health reporting unit — net sales mean?
- The total revenue earned from selling products specifically designed for urological and pelvic health treatments.